Top-Line Results

 
News Articles for Top-Line Results top ^
Exelixis, Inc. (NASDAQ:EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis.
Sign-up for Exelixis Announces Positive Top-Line Results From a Phase 2 Trial of Cabozantinib and Erlotinib in Patients With EGFR Wild-Type Non-Small Cell Lung Cancer investment picks
Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced top-line results from a Phase 2 study of its lead drug candidate, EBI-005, in patients with moderate to severe allergic conjunctivitis.
Sign-up for Eleven Biotherapeutics Announces Top-Line Results from Phase 2 Study of EBI-005 in Patients with Moderate to Severe Allergic Conjunctivitis investment picks
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia inducible factor (HIF), today announced positive top-line results from its Phase 2b placebo-controlled trial of AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary endpoint and AKB-6548 was generally well tolerated, confirming that the once-daily, oral therapy can successfully increase and maintain hemoglobin (HGB) levels.
Sign-up for Akebia Announces Positive Top-Line Results from its Phase 2b Study of AKB-6548 in Non-Dialysis Patients with Anemia Related to Chronic Kidney Disease investment picks
ArQule, Inc. (NASDAQ: ARQL) today announced positive top-line results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial of tivantinib as a single agent in metastatic prostate cancer.
Sign-up for ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer investment picks
Trevena, Inc. (NASDAQ: TRVN), a clinical stage pharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced positive top-line data from its randomized, double-blind, placebo- and active-controlled Phase 2a/b trial of TRV130 in moderate-to-severe postoperative acute pain.
Sign-up for Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain investment picks
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced top line results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) for the treatment of first-line HER2-positive locally recurrent or metastatic breast cancer (NEfERTT trial). The NEfERTT trial is a randomized, two-arm Phase II trial of neratinib plus the anticancer drug paclitaxel versus trastuzumab (Herceptin) plus paclitaxel as a first-line treatment for HER2- positive locally recurrent or metastatic breast cancer.
Sign-up for Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II Trial in HER2 Positive Metastatic Breast Cancer (NEfERTT Trial) investment picks
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced top line results for a Phase 2 clinical trial evaluating Sustained Release Dexamethasone (OTX-DP) for treatment of allergic conjunctivitis.
Sign-up for Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial for Allergic Conjunctivitis investment picks
Met primary efficacy endpoint by successfully restoring testosterone levels to the normal range in 88% of the subjects Lower limit of the 95% confidence interval was 82% 85% of the subjects reached final dose with no more than one dose titration Majority of subjects ended on 225 mg BID Proportion of subjects with maximum serum concentrations generally met FDA pre-specified targets LPCN 1021 treatment was well tolerated with no drug related serious adverse events SALT LAKE CITY, Sept.
Sign-up for Lipocine Announces Positive Top-Line Results in Its Phase 3 Study of LPCN 1021 for Oral Testosterone Replacement Therapy investment picks
Candidate For Once Daily Dosing SALT LAKE CITY, Oct.
Sign-up for Lipocine Announces Positive Top-Line Results in Phase 2a Study of LPCN 1111 investment picks
BI1181181/VTP-37948 Demonstrated Greater Than 80% Reduction of an Alzheimer's Disease Biomarker, the Cerebral Spinal Fluid Amyloid Beta Levels BI1181181/VTP-37948 Was Safe and Generally Well-Tolerated With a Profile Supporting Once-Daily Dosing FORT WASHINGTON, Pa., Oct.
Sign-up for Positive Top-Line Results Achieved From Two Phase 1 Clinical Trials of BACE Inhibitor BI1181181/VTP-37948 in Alzheimer's Disease investment picks
GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that healthy volunteers in a Phase 1 clinical study of GMI-1271 tolerated the drug candidate well, and that the pharmacokinetics for the drug candidate were as predicted based on preclinical data.
Sign-up for GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers investment picks
Primary Efficacy Analysis Demonstrates Clinical Equivalence First Phase 3 Data From Amgen's Biosimilars Program THOUSAND OAKS, Calif.
Sign-up for Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Plaque Psoriasis investment picks
2014/10/31
Conference Call Scheduled for Monday, November 3, 2014 at 10:00 a.m. Eastern time JERUSALEM , October 31, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( http://www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announces that the company will host a conference call to discuss the clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes on Monday, November 3, 2014 at 10:00 a.m. Eastern time .
Sign-up for Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes investment picks
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS INDIANAPOLIS , Dec.
Sign-up for Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis investment picks
All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration Establishes dosing range and regimen for Phase 2 trial design SHELTON, Conn., Dec.
Sign-up for Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Top-Line Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Top Selling  |  Next: Top-Performing Companies